Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
View: Text | PDF
Research Article Cell biology Oncology

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models

  • Text
  • PDF
Abstract

T follicular helper (TFH) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling TFH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of TFH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13hi TFH cells, and its deficiency impaired TFH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key TFH-associated loci, including Cxcr5 and Il6ra. Notably, ginkgolic acid treatment suppressed TFH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during TFH differentiation and suggest that modulation of this pathway may provide a strategy to tune TFH-driven immune responses.

Authors

Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li

×

Figure 3

METTL8 promotes TFH cell differentiation.

Options: View larger image (or click on image) Download as PowerPoint
METTL8 promotes TFH cell differentiation.
(A) Schematic diagram of the m...
(A) Schematic diagram of the mouse model: 2 × 105 B16F10 cells were subcutaneously injected into Mettl8fl/fl Cd4cre and littermate control mice and intraperitoneally injected with anti–PD-1 or IgG every 2 days from days 7 to 11. Mice were analyzed at day 13. (B) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells gated on CD44hiCD62Llo CD4+ T cells in the TdLNs of B16F10 tumor–bearing Mettl8fl/fl Cd4cre and littermate control mice treated with IgG or anti–PD‑1 antibody (n = 5–8/group). (C) Schematic of adoptive transfer: CD45.1+ Mettl8−/− or Ctrl Smarta CD4+ T cells were transferred into CD45.2+ WT recipients, followed by LCMV-Armstrong (LCMV-Arm) 24 h later, and analyzed at 8 dpi. (D) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells in CD45.1+ Smarta CD4+ T cells in spleens of WT recipients (n = 8/group). (E) Schematic of the cotransfer experiment. CD45.2+ Mettl8−/− or Ctrl Smarta CD4+ T cells were primed in vivo for 24 h and transduced with EV-GFP or Mettl8-GFP retrovirus. GFP+ and GFP− cells were sorted and cotransferred at a 1:1 ratio into CD45.1+ WT recipients, followed by LCMV-Armstrong infection 24 h later and analyzed at 8 dpi. (F) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells gated on CD45.2+ Smarta CD4+ T cells in the spleens of mice in E (n = 6/group). Cell counts were normalized to the corresponding WT GFP– group within each experiment. Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 1-way ANOVA (B and F) and 2-tailed Student’s t test (D). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts